Trial NCT04546399

View at ClinicalTrials.gov 
Org. Study IDs: NCI-2020-06813
Secondary IDs: AALL1821 NCI-2020-06813 U10CA180886

Last trial update was posted on 2024-04-18

MeSH Interventions

2-Aminopurine Antibodies Antibodies, Bispecific Antibodies, Monoclonal Antineoplastic Agents, Immunological Asparaginase BB 1101 Blinatumomab Calcium Calcium, Dietary Cyclophosphamide Cytarabine Dexamethasone Dexamethasone acetate Etoposide Etoposide phosphate Folic Acid Hydrocortisone Hydrocortisone 17-butyrate 21-propionate Hydrocortisone acetate Hydrocortisone hemisuccinate Immunoglobulins Leucovorin Levoleucovorin Mercaptopurine Methotrexate Muromonab-CD3 Nivolumab Pegaspargase Podophyllotoxin Thioguanine Vincristine

MeSH Conditions

Down Syndrome Leukemia Leukemia, Lymphoid Precursor Cell Lymphoblastic Leukemia-Lymphoma

Other Conditions

Recurrent B Acute Lymphoblastic Leukemia

Stopping Reasons

Other - FDA Partial Clinical Hold

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID